Sartorius Stedim Biotech Forecast, price target & analysts
Sartorius Stedim Biotech Target price 2026 - Analyst rating & recommendation
Sartorius Stedim Biotech Classifications & Recommendation
Sartorius Stedim Biotech Price Target
| Target Price | €244.29 |
| Price | €198.10 |
| Potential |
23.32%
register free of charge
|
| Number of Estimates | 15 |
|
15 Analysts have issued a price target Sartorius Stedim Biotech 2027 .
The average Sartorius Stedim Biotech target price is €244.29.
This is
23.32%
register free of charge
€275.10
38.87%
register free of charge
€210.08
6.05%
register free of charge
|
|
| A rating was issued by 18 analysts: 17 Analysts recommend Sartorius Stedim Biotech to buy, 1 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Sartorius Stedim Biotech stock has an average upside potential 2027 of
23.32%
register free of charge
|
Sales and Margin forecast 2026, 2027 to 2033
| Dec '25 |
2026 Estimates |
|
|---|---|---|
| Revenue Billion € | 2.97 | 3.16 |
| 6.74% | 6.55% | |
| EBITDA Margin | 28.90% | 31.05% |
| 14.87% | 7.44% | |
| Net Margin | 8.95% | 15.47% |
| 42.10% | 72.84% |
16 Analysts have issued a sales forecast Sartorius Stedim Biotech 2026 . The average Sartorius Stedim Biotech sales estimate is
This results in the following potential growth metrics:
16 Analysts have issued an Sartorius Stedim Biotech EBITDA forecast 2026. The average Sartorius Stedim Biotech EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
16 Sartorius Stedim Biotech Analysts have issued a net profit forecast 2026. The average Sartorius Stedim Biotech net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2026, 2027 to 2033
| Dec '25 |
2026 Estimates |
|
|---|---|---|
| Earnings Per Share € | 2.73 | 5.03 |
| 50.83% | 84.25% | |
| P/E | 39.41 | |
| EV/Sales | 6.72 |
16 Analysts have issued a Sartorius Stedim Biotech forecast for earnings per share. The average Sartorius Stedim Biotech EPS is
This results in the following potential growth metrics and future valuations:
Sartorius Stedim Biotech...
Current Sartorius Stedim Biotech Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| ESN/CIC MARKET SOLUTIONS |
Locked
➜
Locked
|
Locked | Jul 09 2026 |
| BAADER EUROPE / ALPHAVALUE |
Locked
➜
Locked
|
Locked | Jul 01 2026 |
| ODDO BHF |
Locked
➜
Locked
|
Locked | Jun 22 2026 |
| BAADER EUROPE / ALPHAVALUE |
Locked
➜
Locked
|
Locked | Jun 07 2026 |
| HSBC GLOBAL INVESTMENT RESEARCH |
Locked
➜
Locked
|
Locked | May 24 2026 |
| BAADER EUROPE / ALPHAVALUE |
Locked
➜
Locked
|
Locked | May 21 2026 |
| NEPHRON RESEARCH |
Locked
➜
Locked
|
Locked | Apr 23 2026 |
| Analyst Rating | Date |
|---|---|
|
Locked
ESN/CIC MARKET SOLUTIONS:
Locked
➜
Locked
|
Jul 09 2026 |
|
Locked
BAADER EUROPE / ALPHAVALUE:
Locked
➜
Locked
|
Jul 01 2026 |
|
Locked
ODDO BHF:
Locked
➜
Locked
|
Jun 22 2026 |
|
Locked
BAADER EUROPE / ALPHAVALUE:
Locked
➜
Locked
|
Jun 07 2026 |
|
Locked
HSBC GLOBAL INVESTMENT RESEARCH:
Locked
➜
Locked
|
May 24 2026 |
|
Locked
BAADER EUROPE / ALPHAVALUE:
Locked
➜
Locked
|
May 21 2026 |
|
Locked
NEPHRON RESEARCH:
Locked
➜
Locked
|
Apr 23 2026 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
